Cellectis Announces Presentations At Upcoming Conferences

NEW YORK--(BUSINESS WIRE)--Regulatory News:

Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS – Nasdaq: CLLS), on developing immunotherapies based on gene edited CAR-T cells (UCART), today announced presentations at the Piper Jaffray 27th Annual Healthcare Conference and the Oppenheimer 26th Annual Healthcare Conference.